| Date | Time | Source | Headline | Symbol | Company |
| 05/08/2024 | 4:46AM | Alliance News |  MaxCyte shares rise amid double-digit revenue increase | LSE:MXCT | Maxcyte Inc |
| 05/08/2024 | 2:05AM | RNS Regulatory News | MaxCyte, Inc. Filing of Form 10-Q | LSE:MXCT | Maxcyte Inc |
| 05/08/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. First Quarter Results | LSE:MXCT | Maxcyte Inc |
| 05/03/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Notice of AGM | LSE:MXCT | Maxcyte Inc |
| 05/01/2024 | 12:04PM | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 04/10/2024 | 8:05AM | RNS Regulatory News | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 04/03/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights and Block Listing Return | LSE:MXCT | Maxcyte Inc |
| 04/02/2024 | 10:19AM | Alliance News | TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout | LSE:MXCT | Maxcyte Inc |
| 04/02/2024 | 8:05AM | RNS Regulatory News | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 04/02/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 03/20/2024 | 6:16AM | RNS Regulatory News | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 03/20/2024 | 6:05AM | RNS Regulatory News | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 03/13/2024 | 7:54AM | Alliance News | IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25% | LSE:MXCT | Maxcyte Inc |
| 03/13/2024 | 3:05AM | RNS Regulatory News | MaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023 | LSE:MXCT | Maxcyte Inc |
| 03/13/2024 | 3:00AM | RNS Regulatory News | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results | LSE:MXCT | Maxcyte Inc |
| 03/12/2024 | 4:05PM | UK Regulatory | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | LSE:MXCT | Maxcyte Inc |
| 03/06/2024 | 3:58AM | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 03/05/2024 | 3:43PM | Alliance News | EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit | LSE:MXCT | Maxcyte Inc |
| 03/05/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Preliminary FY Results & 2024 Guidance | LSE:MXCT | Maxcyte Inc |
| 03/04/2024 | 4:05PM | UK Regulatory | MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results | LSE:MXCT | Maxcyte Inc |
| 03/01/2024 | 12:57PM | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 02/29/2024 | 4:21AM | RNS Regulatory News | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 02/26/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 02/09/2024 | 8:05AM | RNS Regulatory News | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 02/09/2024 | 8:05AM | UK Regulatory | MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences | LSE:MXCT | Maxcyte Inc |
| 02/01/2024 | 4:24AM | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 01/31/2024 | 2:00AM | RNS Regulatory News | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 9:29AM | RNS Regulatory News | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 8:58AM | Alliance News | IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen | LSE:MXCT | Maxcyte Inc |
| 01/30/2024 | 8:05AM | UK Regulatory | MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers | LSE:MXCT | Maxcyte Inc |